LTC2152290I2 - Anti-il-5 antikūnų skyrimo būdai - Google Patents
Anti-il-5 antikūnų skyrimo būdaiInfo
- Publication number
- LTC2152290I2 LTC2152290I2 LTPA2016005C LTPA2016005C LTC2152290I2 LT C2152290 I2 LTC2152290 I2 LT C2152290I2 LT PA2016005 C LTPA2016005 C LT PA2016005C LT PA2016005 C LTPA2016005 C LT PA2016005C LT C2152290 I2 LTC2152290 I2 LT C2152290I2
- Authority
- LT
- Lithuania
- Prior art keywords
- antibodies
- methods
- administering anti
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91483307P | 2007-04-30 | 2007-04-30 | |
US99071507P | 2007-11-28 | 2007-11-28 | |
PCT/US2008/062015 WO2008134721A1 (en) | 2007-04-30 | 2008-04-30 | Methods for administering anti-il-5 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
LTPA2016005I1 LTPA2016005I1 (lt) | 2018-11-12 |
LTC2152290I2 true LTC2152290I2 (lt) | 2018-12-27 |
Family
ID=39926128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTPA2016005C LTC2152290I2 (lt) | 2007-04-30 | 2016-03-03 | Anti-il-5 antikūnų skyrimo būdai |
Country Status (12)
Country | Link |
---|---|
US (5) | US20100086554A1 (lt) |
EP (4) | EP2152290B1 (lt) |
JP (6) | JP2010526088A (lt) |
CY (1) | CY1115456T1 (lt) |
DK (1) | DK2152290T3 (lt) |
ES (1) | ES2492943T3 (lt) |
HR (1) | HRP20140789T1 (lt) |
LT (1) | LTC2152290I2 (lt) |
PL (1) | PL2152290T3 (lt) |
PT (1) | PT2152290E (lt) |
SI (1) | SI2152290T1 (lt) |
WO (2) | WO2008134724A2 (lt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2152290E (pt) * | 2007-04-30 | 2014-09-03 | Glaxosmithkline Llc | Métodos para administrar anticorpos anti-il-5 |
AU2009228163B2 (en) * | 2008-03-28 | 2012-08-30 | Glaxosmithkline Llc | Methods of treatment |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
CN105175542B (zh) | 2010-12-16 | 2018-12-18 | 弗·哈夫曼-拉罗切有限公司 | 与th2抑制相关的诊断和治疗 |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
CA2924873A1 (en) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
CA2937556A1 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
CA2977285A1 (en) | 2015-03-16 | 2016-09-22 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
KR20180037275A (ko) | 2015-08-24 | 2018-04-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 생물제약 조성물 |
JP7224304B2 (ja) | 2017-05-26 | 2023-02-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 生物医薬組成物および関連の方法 |
JP7295038B2 (ja) | 2017-06-06 | 2023-06-20 | グラクソスミスクライン エルエルシー | 小児患者のための生物薬剤組成物及び方法 |
CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业(上海)股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
JP7418337B2 (ja) | 2018-02-09 | 2024-01-19 | ジェネンテック, インコーポレイテッド | マスト細胞媒介性炎症性疾患の治療法及び診断法 |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
WO2023091608A2 (en) * | 2021-11-18 | 2023-05-25 | Memorial Sloan-Kettering Cancer Center | Methods for treating anti-cancer drug-related skin rashes using benralizumab |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8800397D0 (en) * | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
US5096704A (en) * | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
IT1237881B (it) | 1989-12-12 | 1993-06-18 | Fast Spa | Struttura a profilo complesso, applicabile su apparecchi agitatori, per il bloccaggio di barattoli di vernice, aventi coperchi comunque diversificati |
CA2129445A1 (en) | 1992-02-06 | 1993-08-07 | Chuan-Chu Chou | Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 |
US6056957A (en) | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
US5783184A (en) * | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
US7399837B2 (en) * | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
CN100391977C (zh) | 1994-12-23 | 2008-06-04 | 史密丝克莱恩比彻姆公司 | 用于治疗il-5介导的疾病的重组il-5拮抗剂 |
US5696323A (en) * | 1996-06-25 | 1997-12-09 | Alliedsignal, Inc. | Two bar resonant beam Coriolis rate sensor |
US6248723B1 (en) * | 1997-06-10 | 2001-06-19 | National Jewish Medical And Research Center | Method for treatment of inflammatory disease |
US5858089A (en) * | 1997-08-26 | 1999-01-12 | Martinovic; Zoran | Corn buttering tool |
KR20010031363A (ko) * | 1997-10-22 | 2001-04-16 | 젠스 포니카우 | 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도 |
MXPA04009418A (es) * | 2002-03-29 | 2005-06-08 | Schering Corp | Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos. |
PT2152290E (pt) * | 2007-04-30 | 2014-09-03 | Glaxosmithkline Llc | Métodos para administrar anticorpos anti-il-5 |
US20090035216A1 (en) * | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
JP5035153B2 (ja) * | 2008-07-14 | 2012-09-26 | 市光工業株式会社 | 車両用灯具 |
-
2008
- 2008-04-30 PT PT87471884T patent/PT2152290E/pt unknown
- 2008-04-30 JP JP2010506604A patent/JP2010526088A/ja active Pending
- 2008-04-30 EP EP08747188.4A patent/EP2152290B1/en active Active
- 2008-04-30 EP EP14166504.2A patent/EP2777710A1/en not_active Withdrawn
- 2008-04-30 EP EP13152633.7A patent/EP2606906A1/en not_active Withdrawn
- 2008-04-30 WO PCT/US2008/062019 patent/WO2008134724A2/en active Application Filing
- 2008-04-30 EP EP08780583A patent/EP2152310A4/en not_active Withdrawn
- 2008-04-30 SI SI200831253T patent/SI2152290T1/sl unknown
- 2008-04-30 JP JP2010506602A patent/JP2010526087A/ja not_active Withdrawn
- 2008-04-30 US US12/598,319 patent/US20100086554A1/en not_active Abandoned
- 2008-04-30 DK DK08747188.4T patent/DK2152290T3/da active
- 2008-04-30 PL PL08747188T patent/PL2152290T3/pl unknown
- 2008-04-30 US US12/598,309 patent/US20100086547A1/en not_active Abandoned
- 2008-04-30 ES ES08747188.4T patent/ES2492943T3/es active Active
- 2008-04-30 WO PCT/US2008/062015 patent/WO2008134721A1/en active Application Filing
-
2014
- 2014-08-07 CY CY20141100618T patent/CY1115456T1/el unknown
- 2014-08-20 HR HRP20140789AT patent/HRP20140789T1/hr unknown
- 2014-09-08 JP JP2014182614A patent/JP2015028042A/ja active Pending
-
2015
- 2015-12-10 US US14/965,130 patent/US20160096886A1/en not_active Abandoned
-
2016
- 2016-03-03 LT LTPA2016005C patent/LTC2152290I2/lt unknown
- 2016-09-26 JP JP2016186583A patent/JP2017036296A/ja active Pending
-
2017
- 2017-10-10 US US15/729,019 patent/US20180022799A1/en not_active Abandoned
-
2018
- 2018-06-06 JP JP2018108483A patent/JP2018158934A/ja active Pending
-
2019
- 2019-09-25 JP JP2019174641A patent/JP2020019781A/ja active Pending
- 2019-10-23 US US16/660,972 patent/US20200040073A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2606906A1 (en) | 2013-06-26 |
EP2152290A1 (en) | 2010-02-17 |
WO2008134724A2 (en) | 2008-11-06 |
EP2152290A4 (en) | 2010-06-02 |
JP2017036296A (ja) | 2017-02-16 |
PL2152290T3 (pl) | 2014-11-28 |
CY1115456T1 (el) | 2017-01-04 |
JP2015028042A (ja) | 2015-02-12 |
JP2020019781A (ja) | 2020-02-06 |
PT2152290E (pt) | 2014-09-03 |
SI2152290T1 (sl) | 2014-09-30 |
JP2018158934A (ja) | 2018-10-11 |
EP2152310A2 (en) | 2010-02-17 |
HRP20140789T1 (hr) | 2014-10-10 |
US20200040073A1 (en) | 2020-02-06 |
DK2152290T3 (da) | 2014-08-18 |
LTPA2016005I1 (lt) | 2018-11-12 |
US20160096886A1 (en) | 2016-04-07 |
US20100086554A1 (en) | 2010-04-08 |
EP2152310A4 (en) | 2010-05-26 |
EP2777710A1 (en) | 2014-09-17 |
EP2152290B1 (en) | 2014-06-04 |
JP2010526088A (ja) | 2010-07-29 |
US20100086547A1 (en) | 2010-04-08 |
ES2492943T3 (es) | 2014-09-10 |
US20180022799A1 (en) | 2018-01-25 |
WO2008134721A1 (en) | 2008-11-06 |
JP2010526087A (ja) | 2010-07-29 |
WO2008134724A3 (en) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2016005I1 (lt) | Anti-il-5 antikūnų skyrimo būdai | |
CY2020021I2 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
CY2019004I2 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
CY2017039I1 (el) | Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6 | |
LTC2662091I2 (lt) | Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui | |
SMT201600222B (it) | Formulazione di anticorpi | |
ES2411907T8 (es) | Uso terapéutico de anticuerpos antirreceptor TWEAK | |
HK1223114A1 (zh) | 抗因子 單克隆抗體及其使用方法 | |
FI20075278A0 (fi) | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet | |
DK2066695T3 (da) | Anti-myostatin-antistoffer | |
BRPI0820298A2 (pt) | anticorpos anti-vegf composições e métodos | |
BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
DK2131860T3 (da) | Anti-sclerostin-antistoffer | |
BRPI0820407A2 (pt) | Uso de anticorpos anti-cd40 | |
BRPI0923359A2 (pt) | Anticorpos anti-igf | |
SMP200800042B (it) | Composizioni e metodi di impiego per anticorpi di dickkopf-1 | |
BRPI0809677A2 (pt) | Anticorpos anti-ige | |
BRPI0819165A2 (pt) | Anticorpos anti-vegf | |
DK2234600T3 (da) | Antistofformulering | |
BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
BRPI0907532A2 (pt) | Anticorpos anti-c5ar humanizados | |
CY2013046I2 (el) | Καινοτομος χρηση των αντισωματων αντι il-1bhta | |
DK2643018T3 (da) | Anti-il-6-antistoffer til behandling af oral mucositis | |
BRPI0813514A2 (pt) | anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso | |
BRPI0821777A2 (pt) | Anticorpos biespecíficos bivalentes |